This article is more than 5 years old. Information may no longer be current.

Minimally invasive glaucoma treatment shows encouraging 1-year results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — A suprachoroidal stent may offer relief for patients undergoing cataract surgery who have concurrent high IOP, a presentation here suggested.

E. Randy Craven

“The CyPass Micro-Stent seems to be a nice option for a minimally invasive procedure that is done ab interno. It has excellent safety, and so far the results, as far as what we are seeing with IOP reduction, are favorable,” E. Randy Craven, MD, said at the American Society of Cataract and Refractive Surgery meeting.

The CyPass Micro-Stent (Transcend Medical) consists of a biocompatible, non-degradable polyimide material that is implanted through a 1.5-mm clear corneal incision, acting as a conduit in the supraciliary space. According to Dr. Craven, the device offers three core advantages: It enables controlled cyclodialysis, it increases non-trabecular outflow, and it is minimally invasive.

There were 184 eyes included in the prospective, multicenter, interventional case series conducted by Dr. Craven and colleagues; 93 presented with IOP less than 21 mm Hg, and 91 had a higher pressure.

Of those with higher baseline IOP, 66 patients who presented for 3-month follow-up demonstrated a mean IOP reduction of roughly 40%. The 31 patients who presented for 12-month follow-up showed a roughly 34% decrease.

At last follow-up, no major adverse events had been reported; however, a transient IOP increase of less than 10 mm Hg was observed in 10.5% of patients.

• Disclosure: Dr. Craven is an investigator for Transcend Medical and Glaukos. He is also a former investigator to Solx with investment interest. Coauthor Tsontcho Lanchulev, MD, is CMO of Transcend, and coauthor Magda B. Rau, MD, is a consultant for the company.